Table 2 Eradication rates of Helicobacter pylori infection in the study population.

From: Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study

H. pylori stool antigen test result

Eradication regimen

p valuea

LNDL

MNDL

ACL

Intention to treat

n: 141

n: 142

n: 71

0.001*

Negative (%)

116 (82.27%)

102 (71.83%)

42 (59.15%)

95% CI

75.89–88.65

64.34–79.32

47.44–70.87

Post hoc

p1 = 0.037, p2 < 0.001, p3 = 0.062

Per-protocol

n: 133

n: 125

n: 69

 < 0.001*

Negative (%)

116 (87.22%)

102 (81.6%)

42 (60.87%)

95% CI

81.47–92.97

74.71–88.49

49.1–72.68

Post hoc

p1 = 0.213, p2 < 0.001, p3 = 0.002

  1. aChi square test, *Statistically significant, CI: Confidence interval.
  2. p1: LNDL vs. MNDL; p2: LNDL vs. ACL; p3: MNDL vs. ACL.
  3. LNDL: Levofloxacin, nitazoxanide, doxycycline, lansoprazole.
  4. MNDL: Moxifloxacin, nitazoxanide, doxycycline, lansoprazole.
  5. ACL: Amoxicillin, clarithromycin, lansoprazole.